VivoSeq
Oncology

Thymic Epithelial Tumor

1

Pipeline Programs↗

3

Active Trials↗

1

Companies Involved↗

Thymic Epithelial Tumor is an early-stage landscape with 1 program across 1 company. The most active players are Promontory Therapeutics Inc..

Intelligence

Pipeline Metrics

Competitive Density

19/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

50/100

Attrition Rate

11/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

P

Promontory Therapeutics Inc.

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 21

PT-112

Promontory Therapeutics Inc.

Phase 3
No programs
Approved
No programs

Analysis

Trial Status

9

clinical trials

Unknown status4 · 44%
Recruiting2 · 22%
Completed1 · 11%
Not yet recruiting1 · 11%
Terminated1 · 11%

Clinical Trials

Trial Activity

9 trials

A Prospective, Single-Arm Phase II Clinical Study of Hypofractionated Adjuvant Radiotherapy After Complete Resection for Stage II/III Thymic Epithelial Tumors
Recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT07691619·49 enrolled
A Phase II, Open-Label Trial of PT-112 in Subjects With Thymoma and Thymic Carcinoma
Recruiting·National Cancer Institute (NCI)·Phase 2·NCT05104736·53 enrolled
Rivoceranib in Patients With Metastatic Thymic Epithelial Tumor
Not yet recruiting·SSamsung Medical Center·Phase 2·NCT06200233·40 enrolled
A Study of Pembrolizumab for Patients With Thymic Epithelial Tumor
Completed·SSamsung Medical Center·Phase 2·NCT02607631·33 enrolled
Selinexor in Patients With Advanced Thymic Epithelial Tumor Progressing After Primary Chemotherapy
Terminated·GGeorgetown University·Phase 2·NCT03193437·8 enrolled
Clinical Study of Neoadjuvant PD-1 Antibody (Toripalimab) Plus Chemotherapy for Locally Advanced Thymic Epithelial Tumor
Unknown status·SShanghai Pulmonary Hospital, Shanghai, China·Phase 2·NCT04667793·15 enrolled
Hypofractionated Chemoradiotherapy and Thymosin α1 in Unresectable or Recurrent Thymic Epithelial Tumor
Unknown status·SSun Yat-sen University·Phase 2·NCT03663764·57 enrolled
neoadjuvant_thymic Epithelial Tumor
Unknown status·SSamsung Medical Center·Phase 2·NCT03858582·40 enrolled
A Phase II Study of Palbociclib for Recurrent or Refractory Advanced Thymic Epithelial Tumor
Unknown status·SSamsung Medical Center·Phase 2·NCT03219554·33 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)